An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction
2022 ◽
Vol 18
(1)
◽
pp. 63-73
Keyword(s):
Keyword(s):
2018 ◽
Vol 92
◽
pp. S102-S103
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2020 ◽
Keyword(s):
Keyword(s):
2020 ◽
Vol 181
(1)
◽
pp. 97-105
◽
Keyword(s):
Keyword(s):